BIOBOT SURGICAL PTE. LTD.

About Biobot Surgical Pte Ltd Biobot Surgical is a Singapore-based medical technology company developing digital robotic platforms for precision prostate cancer diagnosis and treatment. Its flagship Mona Lisa platform combines MRI-ultrasound fusion with robotic transperineal guidance to enable precise prostate biopsy and focal therapy. Designed to enhance clinical accuracy and procedural reproducibility, the platform helps physicians accurately target suspicious lesions while preserving healthy tissue. By connecting diagnosis and treatment on a single platform, Mona Lisa facilitates seamless access to clinically relevant information throughout the patient journey, supporting integrated prostate cancer management. Biobot Surgical is evolving the Mona Lisa platform into an integrated digital ecosystem for prostate cancer care, where robotics, medical imaging, artificial intelligence, and longitudinal clinical data converge to enable more precise, reproducible, and personalized patient management.

关于Biobot Surgical Pte Ltd Biobot Surgical是一家总部位于新加坡的医疗科技公司，开发用于精准前列腺癌诊断和治疗的数码机器人平台。 其旗舰产品Mona Lisa平台结合了MRI-超声融合与机器人经会阴引导，实现精准前列腺活检和局部治疗。该平台旨在提高临床准确性和操作可重复性，帮助医生精准靶向可疑病灶，同时保留健康组织。 通过在单一平台上连接诊断和治疗，Mona Lisa促进患者旅程中无缝获取临床相关信息，支持整合性前列腺癌管理。 Biobot Surgical正将Mona Lisa平台发展为前列腺癌护理的整合数码生态系统，让机器人技术、医学成像、人工智能和纵向临床数据汇聚，实现更精准、可重复和个性化的患者管理。